MedPath
FDA Approval

REZZAYO

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Effective Date
June 8, 2023
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Rezafungin(200 mg in 1 1)

Registrants1

Companies and organizations registered with the FDA for this drug approval, including their contact information and regulatory details.

Cidara Therapeutics, Inc.

025485700

Manufacturing Establishments1

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Patheon Italia S.p.A.

Melinta Therapeutics, LLC

Cidara Therapeutics, Inc.

338336589

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

REZZAYO

Product Details

NDC Product Code
70842-240
Application Number
NDA217417
Marketing Category
NDA (C73594)
Route of Administration
INTRAVENOUS
Effective Date
June 8, 2022
Code: G013B5478JClass: ACTIBQuantity: 200 mg in 1 1
MANNITOLInactive
Code: 3OWL53L36AClass: IACT
HYDROCHLORIC ACIDInactive
Code: QTT17582CBClass: IACT
HISTIDINEInactive
Code: 4QD397987EClass: IACT
POLYSORBATE 80Inactive
Code: 6OZP39ZG8HClass: IACT
SODIUM CHLORIDEInactive
Code: 451W47IQ8XClass: IACT
© Copyright 2025. All Rights Reserved by MedPath